

Amendments to the Specification:

Please replace the paragraph found on page 21 at line 33 to page 22, line 17, with the following amended paragraph, where underlining indicates material to be added and ~~strikethrough~~ indicates material to be deleted:

The disclosure of Application No. 07/248,293, now U.S. Patent No. 5,126,131, includes a description of constructs comprising size fractionated linear polyacrylamide chemically modified to accept DNP groups as epitopes. These conjugates can be organized into groups based on the size (molecular weight) of the backbone polymer and hapten number (number of DNP groups per average molecular weight polymer for a given group). The combination of these two ~~sealer~~ scalar quantities makes it possible to determine the role of hapten density as a separate variable. Based on the data obtained using these constructs in both in vitro and in vivo models of immune function, certain "rules" governing B-cell activation by antigen have been elucidated and used to control the T-cell independent immune response on an antigen specific basis. These rules and their use in effecting an antigen specific alteration in immune function are included in Application No. 07/248,293, now U.S. Patent No. 5,126,131.

Please replace the paragraph found on page 22 at lines 18-32 with the following amended paragraph, where underlining indicates material to be added:

Application No. 07/354,710 (now abandoned, from which continuation Application Ser. No. 08/049,601, now Pat. No. 5,370,871, was filed) included further exemplification in support of the application of these rules to include a variety of backbones or scaffolds and haptens, thus further documenting the "universality" of the rules elucidated in the original filing as they apply, particularly, to T-cell independent immune system activities (operationally defined as IgM production). The present disclosure includes specific exemplification which makes clear the applicability of these selfsame rules to a spectrum of immune function, including T-cell dependent antibody production (operationally defined as the production of IgG and IgE) and T-cell activity as well.